{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:58:35Z","timestamp":1784303915067,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023MD734156"],"award-info":[{"award-number":["2023MD734156"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nanchong Science and Technology Bureau Basic Research Platform Project","award":["23JCYJPT0043"],"award-info":[{"award-number":["23JCYJPT0043"]}]},{"name":"Specialty Areas in Oncology, Anesthesiology and Other Fields of Sichuan Medical Association","award":["2024HR03"],"award-info":[{"award-number":["2024HR03"]}]},{"name":"Science and Technology Innovation Platforms and Talent Program of Sichuan Provincial Department of Science and Technology","award":["2024JDKP0022"],"award-info":[{"award-number":["2024JDKP0022"]}]},{"name":"Innovation Team Program of the Affiliated Hospital of North Sichuan Medical College","award":["2024CX002"],"award-info":[{"award-number":["2024CX002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04198-6","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:28:52Z","timestamp":1772152132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic arterial infusion chemotherapy (HAIC) combined with sequential or concurrent systemic targeted immunotherapy for advanced hepatocellular carcinoma: a single-center retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaogang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"3","key":"4198_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"key":"4198_CR2","doi-asserted-by":"publisher","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.\u00a0https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","DOI":"10.1038\/s41572-020-00240-3"},{"issue":"7","key":"4198_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, et al. Sorafenib plus hepatic arterial infusion of Oxaliplatin, Fluorouracil, and leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion. JAMA Oncol. 2019;5(7):953.","journal-title":"JAMA Oncol"},{"issue":"5","key":"4198_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","volume":"70","author":"Q Wang","year":"2019","unstructured":"Wang Q, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70(5):893\u2013903.","journal-title":"J Hepatol"},{"key":"4198_CR5","volume-title":"Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma","author":"Y-z Cao","year":"2024","unstructured":"Cao Y-z, et al. Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma. Volume 74. Immunotherapy: Cancer Immunology; 2024. 1."},{"issue":"10492","key":"4198_CR6","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, et al. Nivolumab plus ipilimumab versus lenvatinib or Sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet (London England). 2025;405(10492):1851\u201364.","journal-title":"Lancet (London England)"},{"issue":"10408","key":"4198_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet (London England). 2023;402(10408):1133\u201346.","journal-title":"Lancet (London England)"},{"issue":"8","key":"4198_CR8","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1016\/j.acra.2024.09.061","volume":"32","author":"P Jiang","year":"2025","unstructured":"Jiang P, et al. Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as First-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and Meta-Analysis. Acad Radiol. 2025;32(8):4595\u2013606.","journal-title":"Acad Radiol"},{"issue":"1","key":"4198_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"Lyu N, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60\u20139.","journal-title":"J Hepatol"},{"key":"4198_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.856818","author":"W Lin","year":"2022","unstructured":"Lin W, et al. Oncological and reproductive outcomes after fertility-sparing surgery for stage I mucinous ovarian carcinoma. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.856818.","journal-title":"Front Oncol"},{"key":"4198_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.729764","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.729764.","journal-title":"Front Oncol"},{"key":"4198_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, et al. Lenvatinib, Toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377.","journal-title":"Eur J Cancer"},{"issue":"20","key":"4198_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/djr351","volume":"103","author":"D Bedognetti","year":"2011","unstructured":"Bedognetti D, et al. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: A multicenter randomized phase III trial. JNCI: J Natl Cancer Inst. 2011;103(20):1529\u201339.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"4198_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1186\/s12885-024-12940-0","volume":"24","author":"L Sun","year":"2024","unstructured":"Sun L, et al. Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study. BMC Cancer. 2024;24(1):1168.","journal-title":"BMC Cancer"},{"issue":"6","key":"4198_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32(6):801\u20135.","journal-title":"Ann Oncol"},{"issue":"2","key":"4198_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"6","key":"4198_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","volume":"21","author":"S Haupt","year":"2021","unstructured":"Haupt S, et al. Sex disparities matter in cancer development and therapy. Nat Rev Cancer. 2021;21(6):393\u2013407.","journal-title":"Nat Rev Cancer"},{"key":"4198_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01663-6","author":"T-Q Zhang","year":"2023","unstructured":"Zhang T-Q, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01663-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"4198_CR19","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","volume":"39","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021;39(10):1375\u2013e13876.","journal-title":"Cancer Cell"},{"key":"4198_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2147\/JHC.S431917","volume":"10","author":"B Yu","year":"2023","unstructured":"Yu B, et al. Tyrosine kinase inhibitors plus Anti-PD-1 antibodies with hepatic arterial infusion chemotherapy or transarterial chemoembolization for unresectable hepatocellular carcinoma. J Hepatocellular Carcinoma. 2023;10:1735\u201348.","journal-title":"J Hepatocellular Carcinoma"},{"issue":"9","key":"4198_CR21","doi-asserted-by":"publisher","first-page":"e099510","DOI":"10.1136\/bmjopen-2025-099510","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu J, Zhang S, Shao H. Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design. BMJ Open. 2025;15(9):e099510.","journal-title":"BMJ Open"},{"issue":"3","key":"4198_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ol.2025.15183","volume":"30","author":"P Jiang","year":"2025","unstructured":"Jiang P, et al. Hepatic artery infusion chemotherapy combined with lenvatinib and PD-1 inhibitors in the treatment of intermediate and advanced unresectable hepatocellular carcinoma. Oncol Lett. 2025;30(3):437.","journal-title":"Oncol Lett"},{"issue":"4","key":"4198_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2021","unstructured":"Cheng A-L, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"2","key":"4198_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint Blockade. Cancer Cell. 2021;39(2):193\u2013e20810.","journal-title":"Cancer Cell"},{"issue":"9","key":"4198_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, et al. Combination of anti-angiogenic therapy and immune checkpoint Blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385.","journal-title":"Exp Mol Med"},{"issue":"8","key":"4198_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M de Ruiz","year":"2019","unstructured":"de Ruiz M, et al. \u03b2-Catenin activation promotes immune escape and resistance to Anti\u2013PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124\u201341.","journal-title":"Cancer Discov"},{"key":"4198_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01213-6","author":"X-Y Huang","year":"2020","unstructured":"Huang X-Y, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis. Mol Cancer. 2020. https:\/\/doi.org\/10.1186\/s12943-020-01213-6.","journal-title":"Mol Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04198-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04198-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04198-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:02:02Z","timestamp":1775264522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04198-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4198"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04198-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been obtained. All authors have approved the final version of the manuscript for submission, and the work described has not been previously published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this study agreed to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}